(Q33676511)

28 July 2017

1 reference

title

Antibiotic resistance problems with Helicobacter pylori (English)

1 reference

28 July 2017

0 references

antibiotic resistance

1 reference

Helicobacter pylori infectious disease

inferred from title

1 reference

Alarcón T

1

1 reference

PubMed ID

10389643

28 July 2017

Domingo D

series ordinal

2

1 reference

PubMed ID

10389643

28 July 2017

López-Brea M

series ordinal

3

1 reference

28 July 2017

1 June 1999

1 reference

International Journal of Antimicrobial Agents

28 July 2017

1 reference

28 July 2017

12

1 reference

28 July 2017

1

1 reference

28 July 2017

19-26

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

28 July 2017

1 reference

7 January 2021

Helicobacter pylori infection and the risk of gastric carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

In vitro activity of omeprazole in combination with several antimicrobial agents against clinical isolates of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Study of the combination of ranitidine bismuth citrate and metronidazole against metronidazole-resistant Helicobacter pylori clinical isolates.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Bactericidal activity and synergy studies of proton pump inhibitors and antibiotics against Helicobacter pylori in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Synergic interactions of macrolides and proton-pump inhibitors against Helicobacter pylori: a comparative in-vitro study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

In vitro synergy testing of clarithromycin and 14-hydroxyclarithromycin with amoxicillin or bismuth subsalicylate against Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Treatment of Helicobacter pylori infection: a review of the world literature

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Resistance of Helicobacter pylori to antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Comparison of three methods for the determination of the sensitivity of Helicobacter pylori to metronidazole.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Antimicrobial susceptibility testing of Helicobacter pylori. Comparison of E-test, broth microdilution, and disk diffusion for ampicillin, clarithromycin, and metronidazole

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

A new semi-solid agar dilution method for determining amoxycillin, clarithromycin and azithromycin MICs for Helicobacter pylori isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Antimicrobial susceptibility testing of 230 Helicobacter pylori strains: importance of medium, inoculum, and incubation time.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Factors affecting growth and antibiotic susceptibility of Helicobacter pylori: effect of pH and urea on the survival of a wild-type strain and a urease-deficient mutant

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Standardization of disk diffusion test and its clinical significance for susceptibility testing of metronidazole against Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

A simple method for determining metronidazole resistance of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

In vitro selection of resistant Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Risk of development of in vitro resistance to amoxicillin, clarithromycin, and metronidazole in Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Mechanism of clarithromycin resistance in clinical isolates of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Appearance of a metronidazole-resistant Helicobacter pylori strain in an infected-ICR-mouse model and difference in eradication of metronidazole-resistant and -sensitive strains

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Demonstration of plasmids in Campylobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Drug resistance of Helicobacter pylori: memorandum from a meeting at the Sixth International Workshop on Campylobacter, Helicobacter, and Related Organisms

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Transformation of Helicobacter pylori by chromosomal metronidazole resistance and by a plasmid with a selectable chloramphenicol resistance marker.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

High frequency of mutations at position 2144 of the 23S rRNA gene in clarithromycin-resistant Helicobacter pylori strains isolated in Spain

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Metabolic activities of metronidazole-sensitive and -resistant strains of Helicobacter pylori: repression of pyruvate oxidoreductase and expression of isocitrate lyase activity correlate with resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Metronidazole uptake by sensitive and resistant isolates of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Genetics of 5-nitroimidazole resistance in Bacteroides species

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Oxygen scavenging, NADH oxidase and metronidazole resistance in Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Anti-helicobacter regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Prevalence of metronidazole resistant Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Evolution of resistance to metronidazole and clarithromycin in Helicobacter pylori clinical isolates from Spain

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Impact of metronidazole resistance on the eradication of Helicobacter pylori.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Metronidazole and clarithromycin resistance in Helicobacter pylori determined by measuring MICs of antimicrobial agents in color indicator egg yolk agar in a miniwell format. The Gastrointestinal Physiology Working Group of Universidad Peruana Cayet

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

High prevalence of Helicobacter pylori metronidazole resistance in migrants to east London: relation with previous nitroimidazole exposure and gastroduodenal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Rapid increase in the prevalence of metronidazole-resistant Helicobacter pylori in the Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Susceptibility of Helicobacter pylori to metronidazole.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Effect of metronidazole resistance on bacterial eradication of Helicobacter pylori in infected children

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Metronidazole-resistant Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Role of metronidazole resistance in therapy of Helicobacter pylori infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Primary resistance to metronidazole and other antibiotics of Helicobacter pylori isolated from children in Poland.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Influence of metronidazole resistance on efficacy of quadruple therapy for Helicobacter pylori eradication

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

One week eradication regimen for Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

One-week triple therapy with omeprazole, amoxycillin and tinidazole for Helicobacter pylori infection: the significance of imidazole resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Ranitidine bismuth citrate therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Patient factors that predict failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Clarithromycin or amoxycillin plus high-dose ranitidine in the treatment of Helicobacter pylori-positive functional dyspepsia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Short-course therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer. ACT-10 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900051-5

7 January 2021

10.1016/S0924-8579(99)00051-5

Identifiers

DOI

1 reference

28 July 2017

1 reference

PubMed ID

10389643